| Bioactivity | MAGE A4 (230-239) is a peptide sequence derived from the MAGE-A4 protein. MAGE A4 (230-239) is an immunogenic epitope that can activate T cells and trigger the killing of tumor cells expressing MAGE-A4. MAGE A4 (230-239) is used in the development of next-generation T cell-based immunotherapies[1]. |
| CAS | 252875-61-9 |
| Sequence | Gly-Val-Tyr-Asp-Gly-Arg-Glu-His-Thr-Val |
| Shortening | GVYDGREHTV |
| Formula | C48H73N15O17 |
| Molar Mass | 1132.18 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Davari K, et al. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy[J]. Journal for Immunotherapy of Cancer, 2021, 9(3). |
MAGE A4 (230-239)
CAS: 252875-61-9 F: C48H73N15O17 W: 1132.18
MAGE A4 (230-239) is a peptide sequence derived from the MAGE-A4 protein. MAGE A4 (230-239) is an immunogenic epitope th
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.